Apart from the well-known PD-1/PD-L1 expression, several emerging markers based on genomic analysis such as tumor mutational burden (TMB) and microsatellite instability (MSI) (5, 6) have a promising performance in predicting ICB efficacy for multiple tumor types. Here, CD274 is linked to neoplasm.